- Argatroban
- Bivalirudin
- Danaparoid
- Fondaparinux – especially in clinically stable patients at average risk of bleeding, and provided normal renal function.
- DOAC:
- Especially in clinically stable patients at average risk of bleeding.
- Most of the published experience in HIT is with rivaroxaban.
Oct
26
2021